ClinicalTrials.gg
CompletedNCT06164756Updated Sep 28, 2026

Long Term Follow Up KET-PD

An observational study in Parkinson's Disease and Depression, sponsored by Yale University. Completed at 1 site in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Yale University · Observational

How we know

Updated Sep 28, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
49
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,650 studies in Parkinson Disease with a site in United States — 305 open to participants now, 387 under way, 7 of them phase 3. Parkinson Disease · United States.

Enrollment
236th of 379
49 · median 78
Started
2023
with 70 others
Observational
381 of 1,650
75 open now
Registered
1,407th of 1,650
by date

Among the 1,650 studies in Parkinson Disease with a site in United States, this one is the 236th largest by enrollment of the 379 observational ones that give a count, is one of 71 that started in 2023, is one of 381 observational ones, and was the 1,407th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

305 of the 1,650 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:

300 more — sign in →

All 305 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,650 studies in Parkinson Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to examine a) the longer-term effects of ketamine for treating depression in Parkinson's disease (PD) and b) the effects of CBT on maintaining the effects of ketamine.

Read the detailed description

This is a roll-out study from the ongoing clinical trial (KET-PD trial; NCT04944017, HIC 2000030394). We will adopt an implementation science approach to have participants across ketamine and placebo groups in one of two arms: a) follow-up with treatment as usual (TAU) (at 3 and 6 months post-infusions); b) follow-up with 3 months of Cognitive Behavior Therapy (CBT) post-infusions, delivered remotely once per week, with follow-up assessments at 3 and 6 month timepoints. CBT is expected to have a superior sustained antidepressant response to the TAU follow-up group in both ketamine and placebo arms. We hypothesize that ketamine + CBT will show the most superior antidepressant response at follow-up.

03

Conditions studied

  • Parkinson's Disease
  • Depression

Keywords

  • Long Term Effect Ketamine Treatment
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

A total of n=56 participants with PD and comorbid depression, age 40-80, are being recruited under the parent clinical trial. As of July 2023, 20 participants have been enrolled. We aim to follow-up our remaining participants longitudinally and, within this, to have 20 prospective participants receive CBT, such that we will have 20 participants in each follow-up arm (CBT vs. TAU), and ultimately 10 in each group (ketamine + CBT, ketamine + TAU, placebo + CBT, placebo + TAU).

Eligibility criteria

Eligibility is determined in the ongoing parent clinical trial (KET-PD trial; NCT04944017, HIC 2000030394).

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
49 participants (actual)
Patient registry
No

Groups and cohorts

  • Experimental: Ketamine Infusion

    Participants who received 6 infusions of ketamine (0.5 mg/kg IV, up to 60 mg total), administered over 40 minutes while on continuous cardiac monitoring and oximetry in the ongoing clinical trial (KET-PD trial; NCT04944017, HIC 2000030394)

    Other: Cognitive Behavior Therapy (CBT) · Other: Treatment As Usual (TAU)

  • Placebo Comparator: Saline Infusion

    Participants who received 6 infusions of placebo (saline IV), administered over 40 minutes while on continuous cardiac monitoring and oximetry in the ongoing clinical trial (KET-PD trial; NCT04944017, HIC 2000030394)

    Other: Cognitive Behavior Therapy (CBT) · Other: Treatment As Usual (TAU)

Interventions

  • OtherCognitive Behavior Therapy (CBT)

    Participants will receive 10 weeks of CBT

  • OtherTreatment As Usual (TAU)

    Participants will receive standard of care treatment

06

What researchers measure

Primary outcomes

  1. Long-Term Change in Depression Severity

    Change in MADRS score following course of ketamine vs. placebo treatment at 3 and 6 month timepoints; and change in MADRS across treatment (ketamine/placebo) and follow-up (CBT/TAU) arms at 3 and 6 month timepoints. The scale used to measure depression severity is called The Montgomery-Åsberg Depression Rating Scale (MADRS). The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. The overall score ranges from 0 to 60, higher MADRS score indicates more severe depression.

    Time frame: 3 Months and 6 Months

Secondary outcomes

  1. Change in Apathy

    Changes in apathy determined by the Starkstein Apathy Scale (SAS) scale

    Time frame: 3 Months and 6 Months

  2. Change in Anxiety

    Changes in anxiety determined by the State-Trait Anxiety Inventory (STAI) scale

    Time frame: 3 Months and 6 Months

  3. Change in Parkinson's Symptom Severity

    Changes in Parkinson's symptom severity determined by the Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scale

    Time frame: 3 Months and 6 Months

  4. Change in Dyskinesia

    Changes in dyskinesia determined by the Unified Dyskinesia Rating Scale (UDysRS) scale

    Time frame: 3 Months and 6 Months

  5. Change in Pain

    Changes in pain determined by the King's PD Pain Scale

    Time frame: 3 Months and 6 Months

  6. Change in Fatigue

    Changes in fatigue determined by the Parkinson's Fatigue Scale (PFS)

    Time frame: 3 Months and 6 Months

  7. Change in Anhedonia

    Changes in anhedonia determined by the Snaith-Hamilton Pleasure Scale (SHAPS)

    Time frame: 3 Months and 6 Months

07

Study locations

1 site
  • Yale New Haven Hospital
    New Haven, Connecticut 06510, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Mar 2026, 28 months.

Of 381 non-industry observational studies under Parkinson Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 133. This study's 28 months is below that.

Counting every sponsor, half of 441 studies reached it within 47 months; a quarter within 22 and three quarters within 114.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 28, 2026: primary completion Dec 2025 → Mar 2026 and completion Dec 2025 → Mar 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2023
First posted
Dec 11, 2023
StartActual
Oct 18, 2023
Primary completionActual
Mar 16, 2026was Dec 2025
CompletionActual
Mar 26, 2026was Dec 2025
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Completed
changed Sep 28, 2026
Primary completion
Dec 21, 2025→Mar 16, 2026 (actual)
Sep 28, 2026
Study completion
Dec 21, 2025→Mar 26, 2026 (actual)
Sep 28, 2026
Enrollment
40 (estimated)→49 (actual)
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Enrolling by invitation→Completed
    Primary completion Dec 21, 2025→Mar 16, 2026 (now actual)
    Study completion Dec 21, 2025→Mar 26, 2026 (now actual)
    Enrollment 40 (estimated)→49 (actual)
    + 2 other changes: verification date and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06164756
Lead sponsor
Yale University
Collaborators
Michael J. Fox Foundation for Parkinson's Research, Yale School of Medicine Center for Brain Mind Health
Responsible party
Sophie Holmes (Assistant Professor of Psychiatry, Yale University) — Principal investigator
First posted
Dec 11, 2023
Start date
Oct 18, 2023
Primary completion
Mar 16, 2026
Completion
Mar 26, 2026
Last update
Sep 28, 2026

Study contacts

Sophie E. Holmes, PhD
principal investigator · Yale University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion